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Harnessing pandemonium: the
clinical implications of tumor
heterogeneity in ovarian cancer
Sarah P. Blagden*
Department of Oncology, Churchill Hospital, University of Oxford, Oxford, UK
Heterogeneity has emerged as a key feature of ovarian cancer between different ovarian
cancer subtypes; within single ovarian cancer subtypes; and within individual patient
tumors. At the genomic level, with the advent of ultra-deep sequencing technologies
alongside RNA-Seq, epigenomics, and proteomics, the complexity surrounding hetero-
geneity has deepened. Here, we summarize the emerging understanding of heterogeneity
in cancer as a whole and the key discoveries in this area relating to ovarian cancer. We
explore the therapeutic limitations and possibilities posed by heterogeneity and how these
will influence the future of ovarian cancer treatment and research.
Keywords: ovarian cancer, heterogeneity, chemotherapy resistance, tumor evolution, HGSOC, clonal evolution,
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Background
Cancer cells within a tumor, rather than being identical, differ greatly from each other in their
morphology, gene expression patterns, metabolism, rates ofmotility, proliferation, and/ormetastatic
potential (1). This is termed as intratumoral heterogeneity (ITH). As a malignant tumor is believed
to arise from a single abnormal cell of origin, the mechanism by which this divergence occurs
has been debated for over 40 years. The pathologist Peter Nowell proposed a “clonal evolution
model” in 1976 whereby an initial neoplastic event in one or more cells confers them with a survival
advantage. Other genetic mutations affecting subsequent generations of cells enhance their survival
and ultimately lead to a highly aneuploid and aggressive mature tumor population (2). Nowell’s
stochastic explanation was challenged following the discovery of bone marrow progenitor cells in
the 1960s and 1970s [e.g., Ref. (3)] leading to the “stem cell model” whereby cancers comprise a
hierarchy of tumorigenic stem cells continuously spawning non-tumorigenic progeny [reviewed by
Ref. (4)]. Subsequent decades of research, advantaged by tools such as high throughput genomic,
epigenetic, and proteomic sequencing, have revealed a much more complex picture. Cancers may
arise from more than one founder cell, contain subpopulations driven by stochastic, stem cell, and
mixed hierarchies, and are exposed to post-transcriptional and environmental influences (such as
hypoxia and acidosis) resulting in their heterogeneity (5–7). Heterogeneity is therefore both genetic,
in which mutations are branded into the genome and carried forward into subsequent generations,
and responsive, whereby expression of genes is altered by environmental factors or in response to
selective pressures. We can conclude that, by the time a tumor is “established” (even at 1 cm3 in size,
it is estimated to contain one billion cancer cells), each mature cell carries founder and acquired
somatic mutations and is highly heterogeneous.
In 1970s, Heppner and others proved the concept that heterogeneity could influence the
chemotherapy response. Heppner used syngeneic xenografts bearing tumors derived from a single
human breast cancer cell line to show that, despite sharing the same parent cell, the established
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xenograft tumors had differential sensitivity to the three main
chemotherapy agents used for breast cancer: cyclophosphamide,
methotrexate, and 5-fluorouracil (8). She noted that the pri-
mary tumor at the site of implantation within these xenografts
was invariably more sensitive to chemotherapy than were
the metastatic deposits. This divergence between primary and
metastatic sites is termed as intertumoral heterogeneity.
In 1970s and 1980s, when cytotoxics were the main anti-cancer
treatments available, the discovery of tumor heterogeneity was
littlemore than a stumbling block to the development of predictive
chemosensitivity assays. Cancer had long been believed to be a
disease of the genome, confirmed by the association between H-
Ras mutation and bladder cancer in 1982 (9). Identification of
the entire spectrum of genes involved in cancer was impossible;
sequencing even a single gene was costly and time-consuming
and the total number of genes within the genome was unknown.
This situation was transformed in a race between academia and
industry to annotate the human genome. The academic Interna-
tional Human Genome Sequencing Consortium (IHGSC) used a
bacterial artificial chromosome (BAC)-to-BAC sequencing tech-
nique in which chromosomes from anonymous donors were cut
into pieces, inserted into BAC clones to generate a library before
being mapped, and then sequenced. Their industrial competitor
Celera (founded by the geneticist and entrepreneur Craig Venter)
opted for a faster, shotgun-sequencing approach in which pieces
of DNA were inserted into a plasmid library before sequencing.
The academics were first to release a working draft of the genome
sequence on the internet in 2000. This was followed in 2001
by publications from IHGSC and Celera (10, 11), respectively.
IHGSC published a final, finished sequence in 2004 (12). Annota-
tion of the human genome and that of other organisms heralded
an “era of genomics” and enriched our understanding of human
evolution and biology.
From the oncology perspective, defining the human genome
sequence provided an essential reference against which the “can-
cer genome” could be compared. In 2004, a census of 291 gene
mutations linked to cancer was published (13). The first intertu-
moral comparison used whole exome sequencing in tumors from
11 patients with colorectal and 11 patients with breast cancer (14).
Initially, the volume of data generated in these types of compara-
tive studies limited the number of tumors that could be sequenced.
This was overcome with the arrival of DNA sequence enrichment
technologies. Since then, the number of tumor types to have been
genetically characterized by whole exome and (to a lesser extent)
whole genome sequencing has expanded dramatically (http://
www.sanger.ac.uk/genetics/CGP/cosmic/papers/). Collaborative
initiatives, such as the International Cancer Genomics Consor-
tium (ICGC), the Cancer Genome Atlas Project (TCGA), and
the Cancer Genome Project (CGP), have pooled the sequencing
data enabling more comprehensive genetic characterization of
cancer types (15). This has expanded the list of known onco-
genic drivers and genemutations regulating pathological signaling
pathways, information that can be used to better define, identify,
or therapeutically target cancer [(13) and subsequently COSMIC
database]. Although around 800,000 somaticmutations have been
identified so far, the vast majority of these are non-physiologically
significant (passenger mutations) with the more potent driver
mutations being of low frequency or as yet undetected in many
cancers. When DNA sequencing data were taken into context
using copy number analysis, RNA expression (cDNA sequenc-
ing or RNA-Seq), and epigenetic profiling, the list of mutations
functionally relevant to each cancer was reduced to an average of
30–60 (16).
The identification of gene mutations associated with cancer
accelerated the drive to replace cytotoxics with “targeted ther-
apies” (usually small molecule inhibitors or monocolonal anti-
bodies). This yielded some notable success stories in which solid
cancers with clear oncogenic drivers, such as the HER2 recep-
tor in breast cancer and mutant B-Raf in melanoma, showed
dramatic clinical responses to the targeted therapies Herceptin
(trastuzumab) and PLX4032 (vemurafenib), respectively (17, 18).
However, the majority of targeted agents were less successful, with
a short-lived or absent clinical response (19). This was particularly
true in epithelial ovarian cancer (EOC). Using the example of
trastuzumab, even in EOC tumors in which HER2 was upregu-
lated, a lack of response to the drug was observed [Teplinsky and
Muggia (20)]. This implied that drivermutations or amplifications
identified in one tumor were not necessarily conserved across
all cancers. An overview of the first wave of targeted therapies
is sobering: of 71 drugs approved by the FDA between 2002
and 2012, the median gain to patients’ overall survival was only
2.1months (21). It was the realization that a therapeutic target
identified on a single, archived tumor sample was perhaps not
representative of the current molecular status of a cancer that
reactivated the issue of tumor heterogeneity.
Tracking Heterogeneity in Epithelial
Ovarian Cancer – The Precursor Lesion
Epithelial ovarian cancer has long been considered a histologically
heterogeneous cancer as it comprises at least five distinct histo-
logical subtypes, the most common and well-studied being high-
grade serous ovarian cancer (HGSOC). At a molecular level, EOC
is also heterogeneous (22). In contrast to cancers that present in
anatomic positionswhere they are quickly detectable, EOC ismost
commonly diagnosed once it has spread outside the pelvis and
into multiple sites around the abdominal cavity. It is probable that
the significant lead-time between developing and detecting EOC
provides the tumor an opportunity to undergo significant clonal
expansion. This is supported by the stage-by-stage deterioration
in prognosis from a 90% 5-year survival at stage I to only 4% if
diagnosed at stage IV (cancerresearchuk.org). An important com-
ponent to “tracking” the accumulation of genetic mutations that
drive the formation and subsequent progression of a cancer is in
identifying its precursor lesion. For ovarian cancer, this has been a
longstanding source of contention [summarized by Ref. (23)]. All
subtypes of EOC were originally believed to arise from dysplastic
squamous epithelial cells covering the ovary or inclusion cysts
formed from invaginations of the ovarian surface epithelium (24).
Subsequent pathological and epidemiological studies suggest dis-
tinct tissues of origin for the main EOC histotypes. For example,
the low-grade endometrioid and clear cell histotypes of EOC are
believed to be derived from endometriotic tissue that hasmigrated
along the fallopian tube onto the ovary (25) and mucinous
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EOC from “Walthard nests,” benign clusters of epithelial cells
with morphological similarities to urothelial tissue present at
tubal–mesothelial junctions (26). The strongest precursor associ-
ation has been made between HGSOC cancers and fallopian tube
premalignant lesions termed as serous tubal intraepithelial car-
cinomas (STICs) located at the tubal–peritoneal junctions. This
discovery came from pathological analyses of specimens collected
at the time of prophylactic salpingo-oophorectomy inwomenwith
an inherited predisposition to ovarian cancer (27). STIC lesions
have also been identified in the fallopian tubes of 70% patients
with sporadic ovarian and serous peritoneal cancer implying its
association is not limited to BRCA carriers (28). However, that
STICs are precursors for all cases of HGSOC is still a matter of
controversy and debate (29, 30). Of note, TP53 mutations have
been identified in STIC lesions and not in inclusion cysts implying
that they might be an early event in HGSOC tumorigenesis and
supporting STICs as bone fide precursor lesions (31). The finding
of a precursor lesion not only facilitates preventative strategies
but also gives an important starting point from which to map
heterogeneity of the disease.
Heterogeneity in Ovarian Cancer
The presence of heterogeneity in EOCwas first formally described
in 1979when ploidywas quantified usingmetaphase spreads from
cells extracted from patients’ ascites before and after chemother-
apy. Thymidine incorporation in ex vivo cells was used to
assess chemotherapy sensitivity. The authors concluded that there
were significant differences in chromosome distribution after
chemotherapy (although overall levels of ploidy were unchanged)
and different chemosensitivity between tumors cells obtained
from distinct metastatic sites (32). Later, with the dawn of recom-
binant DNA technology in the 1990s, genetic studies became
more sophisticated. By analyzing the restriction fragment length
polymorphisms, Ehlen and Dubeau (33) identified significant
chromosomal loss of heterozygosity in chromosomal segments
3p, 6q, and 11p in EOC tumor tissue while Lee et al. (34) demon-
strated allelic loss of chromosomes 6q, 11, and 17. Later, some of
these sites were found to harbor tumor suppressor genes, such as
chromsome 17, which is the genomic location ofBRCA1 andTP53
(35).At this point, polymerase chain reaction (PCR) and fragment
sequencing enabled the identification of mutations within known
cancer-associated genes. Using this technique mutations were
identified in BRCA and P53 (36, 37). Invariably, these analyses
were conducted on single biopsy specimens. In a study published
in 2007, multiple specimens were microdissected from paraffin-
embedded tumors obtained from 22 patient samples and com-
pared using microsatellite and single nucleotide polymorphism
(SNP) analysis. Although all tumors were HGSOC and thus mor-
phologically similar, there was considerable genetic heterogeneity
observed between patients and between samples collected from
the same patient, manifested as chromosome deletions (particu-
larly chromosomes 13 and 17), microsatellite instability, and SNP
variation (38).
Understanding the genetic composition of HGSOC was greatly
enhanced with data from TCGA Research Network. Here
genomic, epigenomic, and transcriptomic expression data from
489 patients with HGSOC were pooled and analyzed for mRNA,
microRNA, DNA copy number, and sites of DNA methylation.
This was correlated with parallel whole exome sequencing, hybrid
affinity capturemethods, and cliniopathological information. The
results confirmed a 96% prevalence of mutations in TP53, 22%
prevalence of BRCA1 or 2mutations, and seven other gene muta-
tions at lower frequency (in 2–6% cases). When compared to 11
other cancer types, ovarian cancer was notable for its low num-
ber of non-synonymous mutations (39). There were, however,
high degrees of somatic copy number alterations, which were
attributed tomutations and promotermethylations affectingDNA
homologous repair genes (40). This was endorsed in studies using
paired-end next generation sequencing and high-density SNP
arrays revealing high copy number and frequent structural vari-
ations (41, 42). Homologous recombination (HR) deficiencies are
present in approximately 50% of HGSOC. The predominant con-
tribution is from somatic BRCA mutations, but as translational
data from the ARIEL2 study of the PARP inhibitor rucaparib
demonstrated, loss-of-function mutations, or homozygous dele-
tion of other HR genes, such as RAD51C also contribute (43). The
TCGA results provided important insights into the transcriptional
landscape of HGSOC. Although only one sample was analyzed
from each patient’s primary tumor (prior to chemotherapy), it
provides an essential basis for comparison, just as the human
genome had done a decade before.
Against the backdrop of heterogeneity research, other groups
have attempted to subclassify ovarian cancer, exemplified by work
fromDavid Bowtell’s group inMelbourne. Using microarray gene
expression profiling on tumor tissue collected from 285 patients
at the time of debulking surgery, they identified six molecular
subtypes of ovarian cancer and correlated their findings with
clinical outcomes (44). Four molecular subtypes of HGSOC were
identified: C1 (high stromal response), C2 (immunoreactive), C4
(low stromal response), and C5 (mesenchymal); the C1 subtype
having the worst survival outcome (45). It is noteworthy that
this method of subclassification identified immunoregulatory and
stromal genes, rather than those involved in DNA repair. For
example, the C1 group was characterized by desmoplasia and
over-expression of myofibroblast markers, such as ACTA2. In
addition, there were variations in T-cells and leukocyte infiltration
(CD3 and CD45 positivity, respectively) between subtypes, with
C2 and C4 subtypes having high intratumoral and stromal CD3
positive cells compared to low intratumoral but high stromal CD3
infiltration in C1 tumors. This method of molecular subtyping
highlights the impact of tumor environment on EOC outcome
and provides an avenue for personalizing treatment. However, an
important caveat is the contribution of tumor heterogeneity and
the likelihood that a single microdissected specimen of tumor
may not be representative of the entire disease. This applies as
much to T cells as to tumor cells. Recent ultra-deep T cell receptor
sequencing in multiple samples collected from patients with renal
cell carcinoma revealed significant heterogeneity in T cell clones
between disease sites (46). Encouragingly, the same might not be
said for tumor-infiltrating lymphocytes (TILs) in EOC. In a study
of high throughput sequencing of the T-cell repertoire in tumor
samples taken during primary debulking surgery, the authors
discovered considerable homogeneity in TILs at different sites of
Frontiers in Oncology | www.frontiersin.org June 2015 | Volume 5 | Article 1493
Blagden Heterogeneity and ovarian cancer
disease. Their findings imply that, in detecting overall TIL activity,
a single tumor biopsy is adequate (47).
Investigations into tumor heterogeneity have evolved from
demonstrating its existence to understanding its patterns of emer-
gence and its clinical implications. In the context of EOC, this
was specifically addressed in 2014 when 27 archived tumor biopsy
samples taken from three patients with advanced (IIIC/IV) pri-
mary EOC were analyzed using a variety of methods, includ-
ing transcriptome and mate-pair sequencing and targeted gene
sequencing (48). Samples were collected from primary and distant
metastatic sites and compared to matched normal tissue samples.
Not only was a high degree of genetic heterogeneity observed
(focusing on approximately 400 oncogenes) within each cancer,
it was clear from the presence and absence of gene mutations in
primary and secondary sites that disseminated cells continued
to evolve independent of the primary tumor, forming genetically
distinct metastatic deposits, which were themselves distinct from
other metastases.
That the evolutionary pattern of cancer can be tracked by spa-
tial tumor sampling has been demonstrated in pancreatic cancer
(49), clear cell renal cancer (50), and HGSOC (51). In the latter
study, 31 samples of HGSOCwere taken from six patients prior to
starting chemotherapy. Exome sequencing, copy number analysis,
target amplicon deep sequencing, and gene expression profil-
ing revealed extensive intratumoral genomic diversity. Although
mutations in well-characterized genes, such as PIK3CA, CTNNB1,
and PDGFR, were observed, they were not present in all samples.
There was no reproducible pattern of evolution between patients;
mutations to TP53 being the only consistent genetic feature
observed. In the Gerlinger study (50), fresh frozen samples were
collected from primary and metastatic sites from four patients
with renal cell cancer. A phylogenetic tree was assembled around
the gene mutations identified in each patient. This demonstrated
that, rather than occurring sequentially and in a linear fashion,
mutations occurred in a branch-like pattern suggesting that tumor
cells in secondary sites had undergone additional mutations that
conferred them with ongoing metastatic potential. This branched
model, visually represented by the figure of a tree, describes the
mutations present in early clonal progenitors as being “trunk”
mutations (52). An example in HGSOC would be the TP53muta-
tions present in STIC lesions that are still ubiquitously present
in metastatic tumor. In contrast, the branches represent later
somatic events that occur following the separation of subclones.
In HGSOC, an example of branch mutations would be PIK3CA,
CTNNB1, and PDGFRmutations that are present in some, but not
all, metastatic sites.
In a recent paper by Schwarz et al. (53), the extent of ITH
was quantified and correlated with clinical outcome. Copy num-
ber profiles from 135 metastatic sites were obtained from 17
patients with HGSOC at the time of diagnosis and following
chemotherapy. Heterogeneity was quantified as the degree of
clonal expansion between tumors (CE-high and CE-low) using
a novel algorithm called minimum event distance for intratumor
copy number comparisons (MEDICC). This computed minimum
event distances between copy number profiles to construct an
evolutionary tree for each patient based on at least three tumor
samples. The results demonstrated significant intratumor genetic
heterogeneity. The authors demonstrated that in eight of nine
patients, the tumor displayed a branched (rather than linear)
pattern of evolution, again suggesting that mutations are ongoing
even at metastatic sites. As the majority had received neoadjuvant
chemotherapy, the authors then quantified CE in samples taken
before and after chemotherapy and showed that chemotherapy
induced only aminimal increase in copynumber events, especially
when compared to the tumor’s inherent heterogeneity. Those with
higher CE had poorer progression-free (10.1months compared
to 12.7months) and overall survival time (23.5months compared
to 42.6months) compared to those with low CE. Because sam-
ples had been collected from two patients at the time of pro-
gression, the authors tracked the percentage of cells expressing
a mutation in NF1 (compared to TP53) in one patient. They
demonstrated increasingly enriched expression of mutant NF1
in the fallopian tube primary, pre-treatment tissue, and post-
treatment samples, and it was also present at relapse in ascitic
fluid. This indicates, albeit in a single patient, that Nowell’s clonal
diversitymodel is correct, a resistant subclonal cellular population
is present at diagnosis, and that CE occurs between diagnosis and
relapse.
Clinical Implications of Tumor
Heterogeneity in Ovarian Cancer
The most obvious clinical implication of tumor heterogeneity is
that a molecularly targeted therapy, while being effective at one
tumor site, may not be as effective at all of them. This would cer-
tainly correlate with the disappointing clinical activity of targeted
therapies in EOC, with the exception perhaps of PARP inhibitors.
There is even a case for avoiding targeted therapies altogether in
the setting of highly heterogeneous tumors. However, findings
from Schwarz et al. (53) and others indicate that some HGSOC
cases are less heterogeneous than others, implying that low CE
patients might benefit from a more targeted approach. Perhaps, a
measure of tumor heterogeneity is as important as tumor staging
in the pre-treatment assessment of the ovarian cancer patient.
However, currentmethods tomeasure heterogeneity require biop-
sies and sequencing of tumor tissue from multiple disease sites
to derive a CE (or equivalent) score, which is impractical in the
routine clinical setting. It is possible that circulating tumor cells
may provide a less invasive means of quantifying overall ITH,
an avenue that is currently being explored in HER2 expressing
breast cancer (54). Deep sequencing of circulating tumor DNA is
another promising technique that has already been used to detect
EGFR mutations acquired during chemotherapy resistance (55).
However, the circulating milieu may not accurately represent that
of the tumor and its surrounding stroma, as was demonstrated by
Emerson et al. (47).
An alternative approach would be to generate a consensus
“evolutionary tree” against which patients could be mapped to
predict their tumor heterogeneity. Although the numbers of EOC
patients in existing evolutionary studies are too low to make these
assumptions, the findings so far show that, for most, the “tree”
of EOC has a short trunk and many branches, representing early
clonal expansion and high genomic instability. It is clear that
algorithms like MEDICC should be used to objectively correlate
the evolutionary maps obtained frommore patients with HGSOC
to observe for similarities in branching patterns and identify
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mutations that drive branching events and share a common path-
way or physiological function. It is possible also that the time to
branching is clinically relevant and tumors with wider trunks and
more clonal mutations will derive greater benefit from targeted
therapies. Greater understanding of the evolutionary tree of EOC
may also help us screen for the emergence of mutations that
drive branching episodes, define which mutations are action-
able (i.e., treatable) and which are unrepresentative of the entire
disease.
A more ambitious aim would be to reverse heterogeneity
with the aim of restoring EOC to a more linear and therefore
more chemotherapy-sensitive evolutionary pattern. This would
depend on identifying and inhibiting the key drivers of hetero-
geneity. To address this, a number of prospective biopsy studies
have been launched with the aim of mapping and tracking the
origin and dissemination of HGSOC over time. This includes
the British Translational Research Ovarian Cancer Collaborative
(BRITROC) study conducted by the BriTROC. As the answer
may not lie in the genome itself, it will be important to look at
transcription efficiency, epigenetic changes, immunological and
stromal contributions, protein expression, and splice variations.
For example, in lung cancer, it has been shown that faulty RNA
editing caused by mutations to the APOBEC cytidine deaminase
protein is an early driver of heterogeneity (56). It is possible
that cytotoxic chemotherapy increases tumor heterogeneity by
augmenting genomic instability, although results from Schwarz
et al. (53) suggest that this is not a major contributor. The
finding of TIL homogeneity across all EOC tumor sites, albeit
in a small cohort of patients, suggests the therapeutic proteins
unaffected by genetic diversity, might prove to be the best cancer
targets.
Conclusion and Future Directions
Ovarian cancer is a highly heterogeneous tumor, evidenced by
the failure of most targeted therapies to make significant impact
against the disease. The degree of heterogeneity adversely cor-
relates with outcome. Emerging data already show a strong and
immediate pattern of clonal evolution (branching) in ovarian
cancer, between diagnosis and recurrence, correspondingwith the
clinical picture of a tumor that is initially responsive but soon
resistant to chemotherapy. The identification of STIC lesions in
the fallopian tube as HGSOC precursors and advances in deep
gene sequencing techniques have opened the door to longitudi-
nal mapping studies and the comparison of heterogeneity across
thousands (rather than tens) of patients. While delineating tumor
heterogeneity might enhance patient stratification and prognosti-
cation, a more important scientific goal lies in the identification of
heterogeneity drivers, not only in HGSOC, but in other less com-
mon histotypes. The therapeutic inhibition of these drivers has the
potential to harness the pandemonium of genetic heterogeneity
and improve response to cancer treatments.
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